ArticleBMC pulmonary medicine2026
Association of triglyceride-glucose index with presence and development of impaired spirometry: results from Austrian LEAD cohort.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe triglyceride-glucose (TyG) index is a marker of metabolic dysfunction. However, evidence regarding its association with lung function (LF) impairment, particularly from longitudinal studies, are scarce. This study aimed to evaluate the association between TyG and both the presence and development of LF impairments.
methodsNine thousand six hundred sixty-eight participants (aged 25-82 yrs; 48% male) who participated in the baseline assessment of the Austrian LEAD cohort and 6,880 individuals with longitudinal follow-up data (mean interval:4.3 yrs) were included in the analysis. Fasting triglycerides and glucose levels were used to calculate the TyG index. Obstructive spirometry, restrictive spirometry, and preserved ratio impaired spirometry (PRISm) were defined using both fixed cut-off and lower limit of normal (LLN) criteria. Associations between the TyG index and lung function parameters, as well as the presence of spirometric impairments at baseline, were examined. In addition, the predictive ability of the TyG index for incident spirometric impairment was assessed.
resultsHigher TyG was significantly associated with lower FEV₁, FVC, MMEF₂₅-₇₅, TLC, and RV. Baseline TyG was associated with higher risk of fixed cut-off defined restrictive spirometry [odds ratio (OR): 1.26 (95% confidence interval (CI): 1.04-1.53)] and PRISm [OR (95% CI): 1.23 (1.00-1.53)], and showed borderline significance for predicting incident restrictive spirometry [risk ratio (RR) (95% CI): 1.50 (0.95-2.40)] over time. Its predictive ability (area under the curve = 0.63) was comparable to established metabolic syndrome indices, including the International Diabetes Federation, Adult Treatment Panel III, and American Heart Association criteria. Sensitivity analyses using LLN-defined spirometric impairment yielded similar results.
conclusionsTyG index is associated with the presence and development of restrictive pulmonary outcomes. However, its standalone predictive value is limited, and its utility may lie in being an easily accessible index rather than a definitive screening tool for impaired lung health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.